<DOC>
	<DOCNO>NCT02252887</DOCNO>
	<brief_summary>The purpose study see combination drug help treat breast cancer . This Phase II study test whether combination drug effective provide information side effect safety . A standard chemotherapy , gemcitabine , combine 2 drug target HER2 receptor . The HER2 receptor growth protein surface breast cancer cell provide message tell breast cancer cell grow . The standard chemotherapy gemcitabine.. The two drug work HER2 . One call trastuzumab ( Herceptin ) commonly give woman advance early HER2 positive breast cancer . The drug , pertuzumab ( Perjeta ) , also give woman advance HER2 positive breast cancer . The drug study individually approve treatment metastatic breast cancer . However , study look effectiveness gemcitabine trastuzumab pertuzumab give woman advance HER2 positive breast cancer prior trastuzumab + pertuzumab pertuzumab-based therapy .</brief_summary>
	<brief_title>Gemcitabine , Trastuzumab , Pertuzumab Treatment Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab , Pertuzumab Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age ≥ 18 Stage IV HER2 ( + ) breast cancer Histologically document HER2 ( + ) breast cancer define IHC 3+ FISH amplification ≥ 2.0 primary metastatic site ; result local lab acceptable . lECOG performance status 0 1 Prior treatment trastuzumab + pertuzumab ( HP ) base therapy pertuzumabbased neoadjuvantadjuvant , unresectable , locally advanced , metastatic setting . ≤ 3 prior chemotherapy metastatic setting . Prior anthracycline , taxane , gemcitabine , antiHER2 agent ( i.e . trastuzumab , pertuzumab , lapatinib , neratinib , TDM1 , etc . ) allow . If patient receive prior gemcitabine , could combine pertuzumab . Patients progression disease current therapy . Measurable nonmeasurable disease . LVEF ≥ 50 % Hematologic parameter : white blood cell ( WBC ) count ≥ 3000/ul , absolute neutrophil count ( ANC ) ≥ 1000/ul , platelet ≥ 100,000/ul , hemoglobin ≥10.0 g/dl Nonhematologic parameter : bilirubin ≤ 1.5 mg/dl , AST/ALT≤ 2.5 x upper limit normal ( ULN ) , alkaline phosphatase ≤ 5 x ULN . Creatinine ≤ 1.5 mg/dl Patients `` treat stable '' brain lesion duration ≥ 2 month may enrol . History prior unstable angina , myocardial infarction , CHF , uncontrolled ventricular arrhythmia within 12 month History prior ≥ G 3 hypersensitivity ( HSR ) toxicity trastuzumab pertuzumab warrant permanent cessation agent History hepatitis B C Pregnant patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gemcitabine ,</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>14-124</keyword>
</DOC>